ARTICLES | MITOCHONDRIA
Targeting Mitochondrial Function in Chronic Disease
By HiToP® USA
June 1, 2026
ARTICLES | MITOCHONDRIA
Targeting Mitochondrial Function in Chronic Disease
By HiToP® USA
June 1, 2026
By HiToP® USA
June 1, 2026
Mitochondrial Dysfunction: A Common Thread in Chronic Disease
Growing research suggests that mitochondrial dysfunction is involved in many chronic and inflammatory conditions. Impaired mitochondrial function can contribute to reduced cellular energy production, increased oxidative stress, altered cellular signaling, and diminished tissue repair capacity. Over time, these changes may contribute to the development and progression of complex chronic diseases.
Mitochondria are responsible for producing ATP, the primary source of cellular energy. Because every repair process, regenerative process, and metabolic process within the body requires energy, mitochondrial health plays a critical role in overall cellular function. When mitochondrial function becomes impaired, cellular performance suffers, potentially affecting tissues and organ systems throughout the body.
As interest continues to grow in therapies that address health at the cellular level, supporting mitochondrial function has become an increasingly important focus in functional and integrative medicine.
The Role of PGC-1α in Mitochondrial Health
One of the most important regulators of mitochondrial function is Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha (PGC-1α).
Activation of PGC-1α is a well-established regulator of mitochondrial function and biogenesis. PGC-1α promotes mitochondrial biogenesis and supports the recycling and replacement of damaged mitochondria, helping maintain a healthy and efficient mitochondrial network.
Increasing PGC-1α levels has been shown to:
- Boost the number and activity of mitochondria
- Improve cellular energy production (ATP)
- Enhance mitochondria-dependent cellular performance
- Support cellular resilience and recovery
- Improve overall metabolic function
- Increase cellular detoxification capacity
- Improve micronutrient utilization
Because of its central role in cellular energy production, PGC-1α has become an important therapeutic target for practitioners seeking to support mitochondrial health and address the underlying cellular dysfunction associated with chronic disease.
How HiToP® Therapy Supports Mitochondrial Function
HiToP® whole-body therapy has emerged as a promising approach for supporting mitochondrial function by stimulating and energizing cellular organelles, including activation of PGC-1α.
When activated, PGC-1α promotes mitochondrial biogenesis and supports the recycling and replacement of damaged mitochondria. By supporting these processes, HiToP® helps improve mitochondrial performance, enhances ATP production, and supports the foundational cellular processes required for healthy tissue function.
Unlike therapies that focus solely on symptom management, HiToP® delivers measurable energy directly to the body’s cells, supporting the cellular energy systems upon which normal physiological function depends. Healthy cellular function requires adequate energy, and mitochondrial performance is fundamental to that process.
Supporting Cellular Function at the Source
Many chronic conditions are associated with impaired cellular energy production and mitochondrial dysfunction. As research continues to highlight the importance of mitochondrial health in chronic disease, therapies that support mitochondrial function are becoming increasingly relevant in clinical practice.
By supporting PGC-1α activity, mitochondrial biogenesis, and ATP production, HiToP® provides practitioners with a unique approach to addressing one of the most fundamental requirements of cellular health: energy. Through support of cellular energy production and mitochondrial performance, HiToP® helps support the foundational cellular processes that contribute to overall health and function.
Clinical Note: The information presented in this article is intended for educational purposes and discussion of published scientific literature. References to physiological mechanisms, clinical findings, and published research do not necessarily reflect FDA-cleared indications for HiToP® High-Tone Therapy. Healthcare providers should exercise their own clinical judgment when evaluating treatment options for individual patients.